Estrogen increases apolipoprotein (Apo) A-I secretion in Hep G2 cells by modulating transcription of the apo A-I gene promoter

被引:50
作者
Lamon-Fava, S [1 ]
Ordovas, JM [1 ]
Schaefer, EJ [1 ]
机构
[1] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Lipid Metab Lab, Boston, MA 02111 USA
关键词
17; beta-estradiol; estrogen receptor; apolipoprotein A-I;
D O I
10.1161/01.ATV.19.12.2960
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Estrogen administration to postmenopausal women has been shown to increase plasma levels of apolipoprotein (apo) A-I. A human hepatoma cell line, Hep G2, was used to test the hypothesis that estrogen increases the hepatic production of apo A-I by modulating gene expression. When Hep G2 cells were treated fur 24 hours with E-2, the apo A-I content in the medium increased 4.3+/-1.0-fold at 10 mu mol/L E-2 and 1.8+/-0.4-fold at 1 mu mol/L E-2 compared with untreated cells. A time-course experiment indicated that there was no E-2-dependent (10 mu mol/L) increase in apo A-I medium content at 1 hour and 2 hours and that apo A-I was 165% of controls at 6 hours and 440% at 24 hours. Hep G2 cells were transfected, by the cationic lipid method, with constructs containing serial deletions of the 5' region of the apo A-I gene (-41/+397, -256/+397, and -2500/+397) cloned in front of the luciferase gene and with or without a 7-kb region spanning the apo C-III/A-IV intergenic region, which has been shown to contain regulatory elements for the expression of the apo A-I gene. With the exception of the construct containing only the basal promoter (-41/+397), the expression of all constructs was 2- to 3-fold greater in the presence of E-2. The smallest construct that maintained E-2 responsiveness,the -256/+397 construct, does not contain a typical estrogen-responsive element. In the same transfection experiments, the 4-fold increase in apo A-I in the culture medium was preserved. However, when the same set of transfections was performed by the calcium phosphate precipitation method, the E-2 effect on the apo A-I content in the culture medium and on transcription activation was nearly abolished. This effect was probably mediated by Ca2+ because incubation of cells with 20 mmol/L CaCl2 abolished the E,response. In conclusion, E-2 increases apo A-I production in hepatic cells by increasing the transcription of the apo A-I gene.
引用
收藏
页码:2960 / 2965
页数:6
相关论文
共 41 条
[1]  
APPLEBAUMBOWDEN D, 1989, J LIPID RES, V30, P1895
[2]  
ARCHER TK, 1986, J BIOL CHEM, V261, P5067
[3]   Transcriptional regulation by steroid hormones [J].
Beato, M ;
Chavez, S ;
Truss, M .
STEROIDS, 1996, 61 (04) :240-251
[4]   ESTROGEN-RESPONSIVE ELEMENT OF THE HUMAN PS2 GENE IS AN IMPERFECTLY PALINDROMIC SEQUENCE [J].
BERRY, M ;
NUNEZ, AM ;
CHAMBON, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (04) :1218-1222
[5]  
BINDER R, 1989, J BIOL CHEM, V264, P16910
[6]   Oral estrogen replacement therapy in postmenopausal women selectively raises levels and production rates of lipoprotein A-I and lowers hepatic lipase activity without lowering the fractional catabolic rate [J].
Brinton, EA .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (03) :431-440
[7]   INTESTINAL APOLIPOPROTEIN AI GENE-TRANSCRIPTION IS REGULATED BY MULTIPLE DISTINCT DNA ELEMENTS AND IS SYNERGISTICALLY ACTIVATED BY THE ORPHAN NUCLEAR RECEPTOR, HEPATOCYTE NUCLEAR FACTOR-4 [J].
GINSBURG, GS ;
OZER, J ;
KARATHANASIS, SK .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :528-538
[8]   HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND CARDIOVASCULAR-DISEASE - 4 PROSPECTIVE AMERICAN-STUDIES [J].
GORDON, DJ ;
PROBSTFIELD, JL ;
GARRISON, RJ ;
NEATON, JD ;
CASTELLI, WP ;
KNOKE, JD ;
JACOBS, DR ;
BANGDIWALA, S ;
TYROLER, HA .
CIRCULATION, 1989, 79 (01) :8-15
[9]   HIGH-DENSITY LIPOPROTEIN AS A PROTECTIVE FACTOR AGAINST CORONARY HEART-DISEASE - FRAMINGHAM STUDY [J].
GORDON, T ;
CASTELLI, WP ;
HJORTLAND, MC ;
KANNEL, WB ;
DAWBER, TR .
AMERICAN JOURNAL OF MEDICINE, 1977, 62 (05) :707-714
[10]   NON-GENOMIC EFFECTS OF CATECHOLESTROGENS IN THE IN-VITRO RAT UTERINE CONTRACTION [J].
GOYACHE, FM ;
GUTIERREZ, M ;
HIDALGO, A ;
CANTABRANA, B .
GENERAL PHARMACOLOGY, 1995, 26 (01) :219-223